Endothelial dysfunction: Methods of assessment and application to hypertension

Current Pharmaceutical Design

Volumn 10, Issue 29, 2004, Pages 3591-3605

  Nadar, Sunil ^a   Blann, Andrew D ^a   Lip, Gregory Y H ^a  

^a CITY HOSPITAL   (United Kingdom)

Author keywords

Endothelial activation; Endothelial damage; Endothelial dysfunction; Hypertension

Indexed keywords

ACETYLCHOLINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN; NITRIC OXIDE; THROMBOMODULIN; VON WILLEBRAND FACTOR;

BLOOD; BLOOD FLOW; BLOOD PRESSURE; BLOOD VESSEL FUNCTION; BLOOD VESSEL TONE; BLOOD VESSEL WALL; CELL ACTIVATION; CIRCULATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; ENDOTHELIUM CELL; ENDOTHELIUM LESION; FOREARM; HUMAN; HYPERTENSION; HYPOXIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; STRESS; VASCULAR DISEASE;

ANIMALS; BIOLOGICAL MARKERS; BLOOD CIRCULATION; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; VASOCONSTRICTION; VASODILATION;

EID: 6344237642     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043382765     Document Type: Review

References (221)

1. Folkow B. Hypertension and endothelial function - aspects of atheroma protection. Blood Press 1992; Suppl. 1: 11-12.
2. Drexler H. Endothelial dysfunction: clinical implications. Prog Cardiovasc Dis 1997; 39(4): 287-324.
3. Docherty JR. Cardiovascular responses in ageing: a review. Pharmacol Rev 1990; 42(2): 103-125.
4. Spieker LE, Noll G, Ruschitzka FT, Maier W, Luscher TF. Working under pressure: the vascular endothelium in arterial hypertension. J Hum Hypertens 2000; 14(10-11): 617-630.
5. Contreras F, Rivera M, Vasquez J, De la Parte MA, Velasco M. Endothelial dysfunction in arterial hypertension. J Hum Hypertens 2000; 14 Suppl 1: S20-S25.
6. Levy BI, Benessiano J, Poitevin P, Safar ME. Endothelium-dependent mechanical properties of the carotid artery in WKY and SHR. Role of angiotensin converting enzyme inhibition. Circ Res 1990; 66(2): 321-328.
7. Shimokawa H. Endothelial dysfunction in hypertension. J Atheroslcer Thromb 1998; 4(3): 118-127.
8. Folkow B. Hypertension and endothelial dysfunction - aspects of atheroma protection. Blood Press 1992; suppl 1: 11-12.
9. Arnal JF, Michel JB, Harrison DG. Nitric oxide in the pathogenesis of hypertension. Curr Opin Nephrol Hypertens 1995; 4(2): 182-188.
10. Cooke JP, Tsao P. Is nitric oxide an endogenous antiathrogenic molecule. Arterioscler Thromb 1994, 14: 653.
11. Clarke JG, Larkin SW, Benjamin N, Keogh BE, Chester A, Davies GJ, et al. Endothelin-1 is a potent long-lasting vasoconstrictor in dog peripheral vasculature in vivo. J Cardiovasc Pharmacol 1989; 13 Suppl 5: S211-S212.
12. Dubey RK, Jackson EK, Luscher TF. Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell. Role of cyclic-nucleotides and angiotensin 1 receptors. J Clin Investig 1995; 96(1): 141-149.
13. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288(5789): 373-376.
14. Bredt DS, Hwang PM, Glatt CE, Lowenstein C, Reed RR, Snyder SH. Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature 1991; 351(6329): 714-718.
15. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333(6174): 664-666.
16. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327(6122): 524-526.
17. Buga GM, Gold ME, Fukuto JM, Ignarro LJ. Shear stress-induced release of nitric oxide from endothelial cells grown on beads. Hypertension 1991; 17(2): 187-193.
18. Weiner CP, Lizasoain I, Baylis SA, Knowles RG, Charles IG, Moncada S. Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci USA 1994; 9(11): 5212-5216.
19. Schmidt HH, Zernikow B, Baeblich S, Bohme E. Basal and stimulated formation and release of L-arginine-derived nitrogen oxides from cultured endothelial cells. J Pharmacol Exp Therap 1990; 254(2): 591-597.
20. Anderson EA, Mark AL. Flow-mediated and reflex changes in large peripheral artery tone ih humans. Circulation 1989; 79(1): 93-100.
21. Stamler JS, Loh E, Roddy MA, Currie KE, Creager MA. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation 1994; 89(5): 2035-2040.
22. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Investig 1989; 83(5): 1774-1777.
23. Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995; 91(5): 1314-1319.
24. Puddu P, Puddu GM, Zaca F, Muscari A. Endothelial dysfunction in hypertension. Acta Cardiologica 2000; 55(4): 221-232.
25. Bernd C, Bernd Noll. Endothelial dysfunction : update and clinical implications. Herz 1999; 24: 62-71.
26. Ghiadoni L, Taddei S, Magagna A. Effects of lacidipine on endothelial function in hypertensive patients. Am J Hypertens 1996; 9: 155a.
27. Mak IT, Boehme P, Weglicki WB. Antioxidant effects of calcium channel blockers against free radical injury in endothelial cells. Correlation of protection with preservation of glutathione levels. Circ Res 1992; 70(6): 1099-1103.
28. Haynes WG, Webb DJ. Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens 1998; 16(8): 1081-1098.
29. de Nucci G, Thomas R, D'Orleans-Juste P, Antunes E, Walder C, Warner TD, et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA 1988; 85(24): 9797-9800.
30. Florijn KW, Derkx FH, Visser W, Hofman JA, Rosmalen FM, Wallenburg HC, et al. Plasma immunoreactive endothelin-1 in pregnant women with and without pre-eclampsia. J Cardiovasc Pharmacol 1991; 17 Suppl 7: S446-S448.
31. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC Jr. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. New Eng J Med 1991; 325(14): 997-1001.
32. Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994; 89(4): 1573-1579.
33. Zeiher AM, Goebel H, Schachinger V, Ihling C. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque. A clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina. Circulation 1995; 91(4): 941-947.
34. Masaki T. Possible role of endothelin in endothelial regulation of vascular tone. Annu Rev Pharmacol Toxicol 1995; 35: 235-255.
35. Furchgott RF, Vanhoutte PM. Endothelium-derived relaxing and contracting factors. FASEB J 1989; 3(9): 2007-2018.
36. Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993; 21(6 Pt 2): 929-933.
37. Katusic ZS, Vanhoutte PM. Superoxide anion is an endothelium-derived contracting factor. Am J Physiol 1989; 257(1 Pt 2): H33-H37.
38. Luscher TF, Vanhoutte PM. Endothelium-dependent responses to platelets and serotonin in spontaneously hypertensive rats. Hypertension 1986; 8(6 Pt 2): II55-II60.
39. Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol 1986, 250(5 Pt 2): H822-H827.
40. Ng KK, Vane JR. Conversion of angiotensin I to angiotensin II. Nature 1967; 216(117): 762-766.
41. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986; 320(6061): 454-456.
42. Yang Z, Arnet U, von Segesser L, Siebenmann R, Turina M, Luscher TF. Different effects of angiotensin-converting enzyme inhibition in human arteries and veins. J Cardiovasc Pharmacol 1993; 22 Suppl 5: S17-S22.
43. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359(6396): 641-644.
44. Emori T, Hirata Y, Marumo F. Specific receptors for endothelin-3 in cultured bovine endothelial cells and its cellular mechanism of action. FEBS Letters 1990; 263(2): 261-264.
45. Jaffe EA. Cell biology of endothelial cells. Hum Pathol 1987; 18: 234-238.
46. Pearson JD. Vessel wall interactions regulating thrombosis. Br Med Bull 1994; 50(4): 776-788.
47. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. New Eng J Med 1992; 326(4): 242-250.
48. Farrell AJ, Williams RB, Stevens CR, Lawrie AS, Cox NL, Blake DR. Exercise induced release of von Willebrand factor: evidence for hypoxic reperfusion microvascular injury in rheumatoid arthritis. Ann Rheum Dis 1992; 51(10): 1117-1122.
49. Kahaleh MB, Osborn I, LeRoy EC. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon. Ann Intern Med 1981; 94(4 pt 1): 482-484.
50. Tsikas D, Boger RH, Bode-Boger SM, Gutzki FM, Frolich JC. Quantification of nitrite and nitrate in human urine and plasma as pentafluorobenzyl derivatives by gas chromatography-mass spectrometry using their 15N-labelled analogs. J Chromatography B: Biomedical Applications 1994; 661(2): 185-191.
51. Braman RS, Hendrix SA. Nanogram nitrite and nitrate determination in environmental and biological materials by vanadium (III) reduction with chemiluminescence detection. Anal Chem 1989; 61(24): 2715-2718.
52. Wennmalm A, Benthin G, Edlund A, Jungersten L, Kieler-Jensen N, Lundin S, et al. Metabolism and excretion of nitric oxide in humans. An experimental and clinical study. Circ Res 1993; 73(6): 1121-1127.
53. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. New Eng J Med 1993; 329(27): 2002-2012.
54. Ignarro LJ. Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu Rev Pharmacol Toxicol 1990; 30: 535-560.
55. Farrell AJ, Blake DR. von Willebrand factor antigen in giant cell arteritis. Ann Rheum Dis 1992, 51(10): 1182.
56. Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol 1990; 6: 217-246.
57. Pottinger BE, Read RC, Paleolog EM, Higgins PG, Pearson JD. von Willebrand factor is an acute phase reactant in man. Thromb Res 1989; 53(4): 387-394.
58. Caekebeke-Peerlinck KM, Koster T, Briet E. Bleeding time, blood groups and von Willebrand factor. Br J Haematol 1989; 73(2): 217-220.
59. Bennett B, Ratnoff OD. Changes in antihemophilic factor (AHF, factor 8) procoagulant activity and AHF-like antigen in normal pregnancy, and following exercise and pneumoencephalography. J Lab Clin Med 1972; 80(2): 256-263.
60. Boneu B, Abbal M, Plante J, Bierme R. Letter: Factor-VIII complex and endothelial damage. Lancet 1975; 1(7922): 1430.
61. Cockcroft JR, Chowienczyk PJ, Benjamin N, Ritter JM. Preserved endothelium-dependent vasodilatation in patients with essential hypertension. New Eng J Med 1994; 330(15): 1036-1040.
62. Taddei S, Virdis A, Ghiadoni L, Salvetti A. Endothelial dysfunction in hypertension: fact or fancy? J Cardiovasc Pharmacol 1998; 32 Suppl 3: S41-S47.
63. Wallberg-Jonsson S, Dahlen GH, Nilsson TK, Ranby M, Rantapaa-Dahlqvist S. Tissue plasminogen activator, plasminogen activator inhibitor-1 and von Willebrand factor in rheumatoid arthritis. Clin Rheumatol 993; 12(3): 318-324.
64. Blann AD, Waite MA. von Willebrand factor and soluble E-selectin in hypertension: influence of treatment and value in predicting the progression of atherosclerosis. Coronary Artery Disease 1996; 7(2): 143-147.
65. Lip GY, Blann AD, Zarifis J, Beevers M, Lip PL, Beevers DG. Soluble adhesion molecule P-selectin and endothelial dysfunction in essential hypertension: implications for atherogenesis? A preliminary report. J Hypertens 1995; 13(12 Pt 2): 1674-1678.
66. Funiak S, Kubisz P, Kvetensky J, Cronberg S. Von Willebrand factor and endothelial damage in essential hypertension. J Hum Hypertens 1995; 9(8): 705.
67. Blann AD, Naqvi T, Waite M, McCollum CN. von Willebrand factor and endothelial damage in essential hypertension. J Hum Hypertens 1993; 7(2): 107-111.
68. Maruyama I, Bell CE, Majerus PW. Thrombomodulin is found on endothelium of arteries, veins, capillaries, and lymphatics, and on syncytiotrophoblast of human placenta. J Cell Biol 1985; 101(2): 363-371.
69. Mitchell CA, Hau L, Salem HH. Control of thrombin mediated cleavage of protein S. Thromb Haemost 1986; 56(2): 151-154.
70. Walker FJ, Sexton PW, Esmon CT. The inhibition of blood coagulation by activated Protein C through the selective inactivation of activated Factor V. Biochimica et Biophysica Acta 1979; 571(2): 333-342.
71. Ishii H, Majerus PW. Thrombomodulin is present in human plasma and urine. J Clin Investig 1985; 76(6): 2178-2181.
72. Seigneur M, Dufourcq P, Conri C, Constans J, Mercie P, Pruvost A, et al. Plasma thrombomodulin: new approach of endothelium damage. Int Angiol 1993; 12(4): 355-359.
73. Boffa MC, Karochkine M, Berard M. Plasma thrombomodulin as a marker of endothelium damage. Nouvelle Revue Francaise d Hematologie 1991; 33(6): 529-530.
74. Takahashi Y, Hosaka Y, Niina H, Nagasawa K, Naotsuka M, Sakai K, et al. Soluble thrombomodulin purified from human urine exhibits a potent anticoagulant effect in vitro and in vivo. Thromb Haemost 1995; 73(5): 805-811.
75. Wada H, Ohiwa M, Kaneko T, Tamaki S, Tanigawa M, Shirakawa S, et al. Plasma thrombomodulin as a marker of vascular disorders in thrombotic thrombocytopenic purpura and disseminated intravascular coagulation. Am J Hematol 1992; 39(1): 20-24.
76. Iba T, Yagi Y, Kidokoro A, Fukunaga M, Fukunaga T. Increased plasma levels of soluble thrombomodulin in patients with sepsis and organ failure. Surgery Today 1995; 25(7): 585-590.
77. Takakuwa T, Endo S, Nakae H, Kikichi M, Suzuki T, Inada K, et al. Plasma levels of TNF-alpha, endothelin-1 and thrombomodulin in patients with sepsis. Res Comm Chem Pathol Pharmacol 1994; 84(3): 261-269.
78. Tomura S, Nakamura Y, Deguchi F, Chida Y, Ohno Y, Kodama S, et al. Plasma von Willebrand factor and thrombomodulin as markers of vascular disorders in patients undergoing regular hemodialysis therapy. Thromb Res 1990; 58(4): 413-419.
79. Morikawa Y, Morikawa A, Makino I. Relationship of thyroid states and serum thrombomodulin (TM) levels in patients with Graves' disease: TM, a possible new marker of the peripheral activity of thyroid hormones. J Clin Endocrinol Metabol 1993; 76(3): 609-614.
80. Iwabuchi S, Yoshida Y, Kamogawa A, Moriyama N, Takatori M, Mizuguchi A, et al. Plasma thrombomodulin in liver diseases. Gastroenterologia Japonica 1990; 25(5): 661.
81. Lindahl AK, Boffa MC, Abildgaard U. Increased plasma thrombomodulin in cancer patients. Thromb Haemost 1993; 69(2): 112-114.
82. Oikawa T, Kushuhara M, Ishikawa S, Hitomi J, Kono A, Iwanaga T, et al. Production of endothelin-1 and thrombomodulin by human pancreatic cancer cells. Br J Cancer 1994; 69(6): 1059-1064.
83. Blann AD, McCollum CN. Circulating endothelial cell/leukocyte adhesion molecules in atherosclerosis. Thromb Haemost 1994; 72(1): 151-154.
84. Ohdama S, Yoshizawa Y, Kubota T, Aoki N. Plasma thrombomodulin as an indicator of thromboembolic disease in systemic lupus erythematosus. Int J Cardiol 1994; 47(1 Suppl): S1-S6.
85. Ohdama S, Takano S, Miyake S, Kubota T, Sato K, Aoki N. Plasma thrombomodulin as a marker of vascular injuries in collagen vascular diseases. Am J Clin Pathol 1994; 101(1): 109-113.
86. Gearing AJ, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993; 14: 506-12.
87. Newman W, Beall LD, Carson CW, Hunder GG, Graben N, Randhawa ZI, et al. Soluble E-selectin is found in supernatants of activated endothelial cells and is elevated in the serum of patients with septic shock. J Immunol 1993; 150(2): 644-654.
88. Gearing AJ, Hemingway I, Pigott R, Hughes J, Rees AJ, Cashman SJ. Soluble forms of vascular adhesion molecules, E-selectin, ICAM-1, and VCAM-1: pathological significance. Ann New York Acad Sci 1992; 667: 324-331.
89. Blann AD, Herrick A, Jayson MI. Altered levels of soluble adhesion molecules in rheumatoid arthritis, vasculitis and systemic sclerosis. Br J Rheumatol 1995; 34(9): 814-819.
90. Geppert A, Graf S, Beckmann R, Hornykewycz S, Schuster E, Binder BR. Concentration of endogenous tPA antigen n coronary artery disease. Relation to thrombotic events, aspirin treatment, hyperlipidemia and multivessel disease. Arterioscler Thromb Vasc Biol 1998; 18: 1634-1642.
91. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DL, Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 1994; 343: 940-943.
92. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165-1168.
93. Underwood MJ, De Bono DP. Increased fibrinolytic activity in the intima of atheromatous coronary arteries: protection at a price. Cardiovasc Res 1993; 27: 882-885.
94. Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu KK. Association of fibrinolytic parameters with early atherosclerosis. The ARIC study. Circulation 1995; 91: 284-290.
95. Stein CM, brown N, Vaughan DE, lang CC, Wood AJ. Regulation of local tissue type plasminogen activator rlease by endothelium dependent and endohelium independant agonists in human vasculature. J Am Coll Cardiol 1998; 32: 117-122.
96. Newby DE, Wright RA, labinloh C, Ludlam CA, Fox KA, Boon NA. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocaridal infarction. Circulation 1999; 99: 1411-1415.
97. De Bono DP. Significance of raised plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease. Br Heart J 1994; 71: 504-507.
98. Sayama H, Nakamura Y, Saito N, Konoshita M. Does the plasma endothelin-1 concentration reflect atherosclerosis in the elderly? Gerontology 1999; 45(6): 312-316.
99. Migdalis IN, Kalogeropoulou K, Iiopoulou V, Varvarigos N, Karmaniolas KD, Mortzos G, et al. Progression of carotid atherosclerosis and the role of endothelin in diabetic patients. Res Commun Mol Pathol Pharmacol 2000; 108(1-2): 27-37.
100. Cardillo C, Campia U, Bryant MB, Panza JA. Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation 2002; 106(14): 1783-1787.
101. Haak T, Jungmann E, Raab C, Usadel KH. Elevated endothelin-1 levels after cigarette smoking. Metabolism: Clinical & Experimental 1994; 43(3): 267-269.
102. Haak T, Marz W, Jungmann E, Hausser S, Siekmeier R, Gross W, et al. Elevated endothelin levels in patients with hyperlipoproteinemia. Clinical Investigator 1994; 72(8): 580-584.
103. Pearson JD. Normal endothelial cell function. Lupus 2000; 9(3): 183-188.
104. Geng YJ, Libby P. Evidence for apoptosis in advanced human atheroma. Colocalization with interleukin-1 beta-converting enzyme. Am J Pathol 1995; 147(2): 251-266.
105. Pepper MS, Sappino AP, Stocklin R, Montesano R, Orci L, Vassalli JD. Upregulation of urokinase receptor expression on migrating endothelial cells. J Cell Biol 1993; 122(3): 673-684.
106. Vassalli JD, Sappino AP, Belin D. The plasminogen activator/plasmin system. J Clin Investig 1991; 88(4): 1067-1072.
107. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. New Eng J Med 1985; 312(3): 159-163.
108. Baj Z, Kowalski J, Kantorski J, Pokoca L, KoSmider M, Pawlicki L, et al. The effect of short-term myocardial ischemia on the expression of adhesion molecules and the oxidative burst of coronary sinus blood neutrophils. Atherosclerosis 1994; 106(2): 159-168.
109. Solovey A, Lin Y, Browne P, Choong S, Wayner E, Hebbel RP. Circulating activated endothelial cells in sickle cell anemia. New Eng J Med 1997; 337(22): 1584-1590.
110. George F, Brouqui P, Boffa MC, Mutin M, Drancourt M, Brisson C, et al. Demonstration of Rickettsia conorii-induced endothelial injury in vivo by measuring circulating endothelial cells, thrombomodulin, and von Willebrand factor in patients with Mediterranean spotted fever. Blood 1993; 82(7): 2109-2116.
111. Drancourt M, George F, Brouqui P, Sampol J, Raoult D. Diagnosis of Mediterranean spotted fever by indirect immunofluorescence of Rickettsia conorii in circulating endothelial cells isolated with monoclonal antibody-coated immunomagnetic beads. J Infect Dis 1992; 166(3): 660-663.
112. Lefevre P, George F, Durand JM, Sampol J. Detection of circulating endothelial cells in thrombotic thrombocytopenic purpura. Thromb Haemost 1993; 69(5): 522.
113. Percivalle E, Revello MG, Vago L, Morini F, Gerna G. Circulating endothelial giant cells permissive for human cytomegalovirus (HCMV) are detected in disseminated HCMV infections with organ involvement. J Clin Investig 1993; 92(2): 663-670
114. Grefte A, van der GM, van Son W, The TH. Circulating cytomegalovirus (CMV)-infected endothelial cells in patients with an active CMV infection. J Infect Dis 1993; 167(2): 270-277.
115. Mutin M, Canavy I, Blann A, Bory M, Sampol J, Dignat-George F. Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells. Blood 1999; 93(9): 2951-2958.
116. Makin A, Chung NA, Blann A, Lip GY. Assessment of endothelial damage in atherosclerotic vascular disease by quantification of circulating endothelial cells: relationship with von Willebrand factor and tissue factor. Eur Heart J 2003; In press.
117. Tio RA, Monnink SH, Amoroso G, Jessurun GA, Veeger N, Volkers C, et al. Safety evaluation of routine intracoronary acetylcholine infusion in patients undergoing a first diagnostic coronary angiogram. J Investig Med 2002; 50(2): 133-139.
118. Monnink SH, van Haelst PL, van Boven AJ, Stroes ES, Tio RA, Plokker TW, et al. Endothelial dysfunction in patients with coronary artery disease: a comparison of three frequently reported tests. J Investig Med 2002; 50(1): 19-24.
119. Li J, Zhao SP, Li XP, Zhuo QC, Gao M, Lu SK. Non-invasive detection of endothelial dysfunction in patients with essential hypertension. Int J Cardiol 1997; 61(2): 165-169.
120. Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001; 104(2): 191-196.
121. Schroeder S, Enderle MD, Ossen R, Meisner C, Baumbach A, Pfohl M, et al. Noninvasive determination of endothelium-mediated vasodilation as a screening test for coronary artery disease: pilot study to assess the predictive value in comparison with angina pectoris, exercise electrocardiography, and myocardial perfusion imaging. Am Heart J 1999; 138(4 Pt 1): 731-739.
122. Muiesan ML, Salvetti M, Monteduro C, Corbellini C, Guelfi D, Rizzoni D, et al. Flow-mediated dilatation of the brachial artery and left ventricular geometry in hypertensive patients. J Hypertens 2001; 19(3 Pt 2): 641-647.
123. Kimura Y, Matsumoto M, Den YB, Iwai K, Munehira J, Hattori H, et al. Impaired endothelial function in hypertensive elderly patients evaluated by high resolution ultrasonography. Can J Cardiol 1999; 15(5): 563-568.
124. Luscher TF, Vanhoutte PM, Raij L. Antihypertensive treatment normalizes decreased endothelium-dependent relaxations in rats with salt-induced hypertension. Hypertension 1987; 9(6 Pt 2): III193-III197.
125. Takase B, Uehata A, Akima T, Nagai T, Nishioka T, Hamabe A, et al. Endothelium-dependent flow-mediated vasodilation in coronary and brachial arteries in suspected coronary artery disease. Am J Cardiol 1998; 82(12): 1535-1539.
126. Park JB, Charbonneau F, Schiffrin EL. Correlation of endothelial function in large and small arteries in human essential hypertension. J Hypertens 2001; 19(3): 415-420.
127. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39(2): 257-265.
128. Sramek A, Bosch JG, Reiber JH, Van Oostayen JA, Rosendaal FR. Ultrasound assessment of atherosclerotic vessel wall changes: reproducibility of intima-media thickness measurements in carotid and femoral arteries. Invest Radiol 2000; 35(12): 699-706.
129. Csanyi A, Egervari A. Simple clinical method of average intima-media thickness measurement in the common carotid artery. Vasa 1996; 25(3): 242-248.
130. Espeland MA, Craven TE, Riley WA, Corson J, Romont A, Furberg CD. Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke 1996; 27(3): 480-485.
131. Furumoto T, Fujii S, Saito N, Mikami T, Kitabatake A. Relationships between brachial artery flow mediated dilation and carotid artery intima-media thickness in patients with suspected coronary artery disease. Jpn Heart J 2002; 43(2): 117-125.
132. Hashimoto M, Eto M, Akishita M, Kozaki K, Ako J, Iijima K, et al. Correlation between flow-mediated vasodilatation of the brachial artery and intima-media thickness in the carotid artery in men. Arterioscler Thromb Vasc Biol 1999; 19(11): 2795-2800.
133. Enderle MD, Schroeder S, Ossen R, Meisner C, Baumbach A, Haering HU, et al. Comparison of peripheral endothelial dysfunction and intimal media thickness in patients with suspected coronary artery disease. Heart 1998; 80(4): 349-354.
134. Ramsis N, El Hawary AA, Ismail E. Relation between carotid intima-media thickness, platelet surface activation and endothelial cell markers. Haemostasis 1998; 28(5): 268-275.
135. Poredos P, Orehek M, Tratnik E. Smoking is associated with dose-related increase of intima-media thickness and endothelial dysfunction. Angiology 1999; 50(3): 201-208.
136. Millgard J, Hagg A, Sarabi M, Lind L. Captopril, but not nifedipine, improves endothelium-dependent vasodilation in hypertensive patients. J Hum Hypertens 1998; 12(8): 511-516.
137. Higashi Y, Sasaki S, Nakagawa K, Ueda T, Yoshimizu A, Kurisu S, et al. A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: a multicenter study. J Am Coll Cardiol 2000; 35(2): 284-291.
138. Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A. Antihypertensive drugs and reversing of endothelial dysfunction in hypertension. Curr Hypertens Rep 2000; 2(1): 64-70.
139. Tomiyama H, Kimura Y, Mitsuhashi H, Kinouchi T, Yoshida H, Kushiro T, et al. Relationship between endothelial function and fibrinolysis in early hypertension. Hypertension 1998; 31(1 Pt 2): 321-327.
140. Makris TK, Stavroulakis GA, Krespi PG, Hatzizacharias AN, Triposkiadis FK, Tsoukala CG, et al. Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol. Am J Hypertens 2000; 13(7): 783-788.
141. Spencer CG, Gurney D, Blann AD, Beevers DG, Lip GY. Von Willebrand factor, soluble P-selectin, and target organ damage in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Hypertension 2002; 40(1): 61-66.
142. Raij L. Nitric oxide in hypertension: relationship with renal injury and left ventricular hypertrophy. Hypertension 1998; 31(1 Pt 2): 189-193.
143. Haller H. Hypertension, the endothelium and the pathogenesis of chronic vascular disease. Kidney Blood Press Res 1996; 19(3-4): 166-171.
144. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 1993; 87(5): 1468-1474.
145. Egashira K, Suzuki S, Hirooka Y, Kai H, Sugimachi M, Imaizumi T, et al. Impaired endothelium-dependent vasodilation of large epicardial and resistance coronary arteries in patients with essential hypertension. Different responses to acetylcholine and substance P. Hypertension 1995; 25(2): 201-206.
146. Ghiadoni L, Taddei S, Virdis A, Sudano I, Di L, V, Meola M, et al. Endothelial function and common carotid artery wall thickening in patients with essential hypertension. Hypertension 1998; 32(1): 25-32.
147. Taddei S, Virdis A, Mattei P, Ghiadoni L, Fasolo CB, Sudano I, et al. Hypertension causes premature aging of endothelial function in humans. Hypertension 1997; 29(3): 736-743.
148. Lip GY, Beevers DG. Abnormalities of rheology and coagulation in hypertension. J Hum Hypertens 1994; 8(9): 693-702.
149. De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Investig 1995; 96(1): 60-68.
150. Luscher TF. The endothelium, in hypertension: bystander, target or mediator? J Hypertens - Supplement 1994; 12(10): S105-S116.
151. Harrison DG, Cai H, Landmesser U, Griendling KK. Interactions of angiotensin II with NAD(P)H oxidase, oxidant stress and cardiovascular disease. J Renin Angiotensin Aldosterone Syst 2003; 4(2): 51-61.
152. Garcia-Cardena G, Comander J, Anderson KR, Blackman BR, Gimbrone MA, Jr. Biomechanical activation of vascular endothelium as a determinant of its functional phenotype. Proc Natl Acad Sci USA 2001; 98(8): 4478-4485.
153. Blann AD, Lip GY. Cell adhesion molecules in cardiovascular disease and its risk factors - what can soluble levels tell us? J Clin Endocrinol Metab 2000; 85(5): 1745-1747.
154. Taddei S, Virdis A, Mattei P, Ghiadoni L, Gennari A, Fasolo CB, et al. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation 1995; 91(7): 1981-1987.
155. Creager MA, Cooke JP, Mendelsohn ME, Gallagher SJ, Coleman SM, Loscalzo J, et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Investig 1990; 86(1): 228-234.
156. Celermajer DS, Adams MR, Clarkson P, Robinson J, McCredie R, Donald A, et al. Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. New Eng J Med 1996; 334(3): 150-154.
157. Taddei S, Virdis A, Mattei P, Arzilli F, Salvetti A. Endothelium-dependent forearm vasodilation is reduced in normotensive subjects with familial history of hypertension. J Cardiovasc Pharmacol 1992; 20 Suppl 12: S193-S195.
158. Vallance P, Collier J. Biology and clinical relevance of nitric oxide. BMJ 1994; 309(6952): 453-457.
159. Forte P, Copland M, Smith LM, Milne E, Sutherland J, Benjamin N. Basal nitric oxide synthesis in essential hypertension. Lancet 1997; 349(9055): 837-842.
160. Hirooka Y, Imaizumi T, Masaki H, Ando S, Harada S, Momohara M, et al. Captopril improves impaired endothelium-dependent vasodilation in hypertensive patients. Hypertension 1992; 20(2): 175-180.
161. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. New Eng J Med 1990; 323(1): 22-27.
162. Hirooka Y, Imaizumi T, Harada S, Masaki H, Momohara M, Tagawa T, et al. Endothelium-dependent forearm vasodilation to acetylcholine but not to substance P is impaired in patients with heart failure. J Cardiovasc Pharmacol 1992; 20 Suppl 12: S221-S225.
163. Linder L, Kiowski W, Buhler FR, Luscher TF. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. Circulation 1990; 81(6): 1762-1767.
164. Patel ST, Kent KC. Risk factors and their role in the diseases of the arterial wall. Semin Vasc Surg 1998; 11(3): 156-168.
165. McIntyre M, Dominiczak AF. Nitric oxide and cardiovascular disease. Postgrad Med J 1997; 73(864): 630-634.
166. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989; 2(8670): 997-1000.
167. Nakazono K, Watanabe N, Matsuno K, Sasaki J, Sato T, Inoue M. Does superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci USA 1991; 88(22): 10045-10048.
168. Maxwell SR, Lip GY. Free radicals and antioxidants in cardiovascular disease. Br J Clin Pharmacol 1997; 44(4): 307-317.
169. Tse WY, Maxwell SR, Thomason H, Blann A, Thorpe GH, Waite M, et al. Antioxidant status in controlled and uncontrolled hypertension and its relationship to endothelial damage. J Hum Hypertens 1994; 8(11): 843-849.
170. Tschudi MR, Mesaros S, Luscher TF, Malinski T. Direct in situ
171. Grunfeld S, Hamilton CA, Mesaros S, McClain SW, Dominiczak AF, Bohr DF, et al. Role of superoxide in the depressed nitric oxide production by the endothelium of genetically hypertensive rats. Hypertension 1995; 26(6 Pt 1): 854-857.
172. Engler MM, Engler MB, Malloy MJ, Chiu EY, Schloetter MC, Paul SM, et al. Antioxidant vitamins C and E improve endothelial function in children with hyperlipidemia: Endothelial Assessment of Risk from Lipids in Youth (EARLY) Trial. Circulation 2003; 108(9): 1059-1063.
173. Erbs S, Gielen S, Linke A, Mobius-Winkler S, Adams V, Baither Y, et al. Improvement of peripheral endothelial dysfunction by acute vitamin C application: different effects in patients with coronary artery disease, ischemic, and dilated cardiomyopathy. Am Heart J 2003; 146(2): 280-285.
174. Antoniades C, Tousoulis D, Tentolouris C, Toutouza M, Marinou K, Goumas G, et al. Effects of antioxidant vitamins C and E on endothelial function and thrombosis/fibrinolysis system in smokers. Thromb Haemost 2003; 89(6): 990-995.
175. Desideri G, Marinucci MC, Tomassoni G, Masci PG, Santucci A, Ferri C. Vitamin E supplementation reduces plasma vascular cell adhesion molecule-1 and von Willebrand factor levels and increases nitric oxide concentrations in hypercholesterolemic patients. J Clin Endocrinol Metab 2002; 87(6): 2940-2945.
176. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104(22): 2673-2678.
177. Haynes WG, Hand MF, Johnstone HA, Padfield PL, Webb DJ. Direct and sympathetically mediated venoconstriction in essential hypertension. Enhanced responses to endothelin-1. J Clin Investig 1994; 94(4): 1359-1364.
178. Yoshida M, Nonoguchi H, Owada A, Ishiyama S, Maeda Y, Ando K, et al. Three cases of malignant hypertension: the roles of endothelin-1 and the renin-angiotensin-aldosterone system. Clin Nephrol 1994; 42(5): 295-299.
179. Schiffrin EL, Deng LY, Sventek P, Day R. Enhanced expression of endothelin-1 gene in resistance arteries in severe human essential hypertension. J Hypertens 1997; 15(1): 57-63.
180. Wagner O, Christ G. Polar secretion of endothlin 1 by cultured endothelial cells. J Biomed Chem 1992; 267: 16066-16068.
181. Schiffrin EL, Deng LY, Larochelle P. Blunted effects of endothelin upon small subcutaneous resistance arteries of mild essential hypertensive patients. J Hypertens 1992; 10(5): 437-444.
182. Yang ZH, Richard V, von Segesser L, Bauer E, Stulz P, Turina M, et al. Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries. A new mechanism of vasospasm? Circulation 1990; 82(1): 188-195.
183. Noll G, Wenzel RR, Schneider M, Oesch V, Binggeli C, Shaw S, et al. Increased activation of sympathetic nervous system and endothelin by mental stress in normotensive offspring of hypertensive parents. Circulation 1996; 93(5): 866-869.
184. Tschudi MR, Luscher TF. Age and hypertension differently affect coronary contractions to endothelin-1, serotonin, and angiotensins. Circulation 1995; 91(9): 2415-2422.
185. Aigbe A, Famodu AA. Haemorheological and fibrinolytic activity in hypertensive Nigerians. Clin Hemorheol Microcirc 1999; 21(3-4): 415-420.
186. Makris TK, Stavroulakis GA, Krespi PG, Hatzizacharias AN, Triposkiadis FK, Tsoukala CG, et al. Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol. Am J Hypertens 2000; 13(7): 783-788.
187. Underwood MJ, De Bono DP. Increased fibrinolytic activity in the intima of atheromatous coronary arteries: protection at a price. Cardiovasc Res 1993; 27(5): 882-885.
188. Ahaneku JE, Sakata K, Urano T, Takada Y, Takada A. Influence of baseline values on lipids, lipoproteins and fibrinolytic parameters during amlodipine treatment of hypertension in Japanese patients. Pharmacol Res 2000; 41(1): 75-79.
189. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. New Eng J Med 1995; 332(10): 635-641.
190. Cortellaro M, Boschetti C, Cofrancesco E, Zanussi C, Catalano M, de Gaetano G, et al. The PLAT Study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. PLAT Study Group. Progetto Lombardo Atero-Trombosi (PLAT) Study Group. Arterioscler Thromb 1992; 12(9): 1063-1070.
191. Gerhard M, Roddy MA, Creager SJ, Creager MA. Aging progressively impairs endothelium-dependent vasodilation in forearm resistance vessels of humans. Hypertension 1996; 27(4): 849-853.
192. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC, et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990; 81(2): 491-497.
193. Taddei S, Virdis A, Ghiadoni L, Mattei P, Sudano I, Bernini G, et al. Menopause is associated with endothelial dysfunction in women. Hypertension 1996; 28(4): 576-582.
194. Casino PR, Kilcoyne CM, Quyyumi AA, Hoeg JM, Panza JA. The role of nitric oxide in endothelium-dependent vasodilation of hypercholesterolemic patients. Circulation 1993; 88(6): 2541-2547.
195. Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1996; 27(3): 567-574.
196. Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Investig 1996; 97(1): 22-28.
197. Heitzer T, Yla-Herttuala S, Luoma J, Kurz S, Munzel T, Just H, et al. Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia. Role of oxidized LDL. Circulation 1996; 93(7): 1346-1353.
198. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997; 95(5): 1119-1121.
199. Radomski MW, Palmer RM, Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 1987; 92(3): 639-646.
200. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991; 88(11): 4651-4655.
201. Rizzoni D, Porteri E, Castellano M, Bettoni G, Muiesan ML, Tiberio G, et al. Endothelial dysfunction in hypertension is independent from the etiology and from vascular structure. Hypertension 1998; 31(1 Pt 2): 335-341.
202. Modena MG, Bonetti L, Coppi F, Bursi F, Rossi R. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol 2002; 40(3): 505-510.
203. Blann A. von Willebrand factor and the endothelium in vascular disease. Br J Biomed Sci 1993; 50(2): 125-134.
204. Blann AD, Tse W, Maxwell SJ, Waite MA. Increased levels of the soluble adhesion molecule E-selectin in essential hypertension. J Hypertens 1994; 12(8): 925-928.
205. Lip GY, Blann AD, Edmunds E, Beevers DG. Baseline abnormalities of endothelial function and thrombogenesis in relation to prognosis in essential hypertension. Blood Coagul Fibrinolysis 2002; 13(1): 35-41.
206. Blann AD, McCollum CN, Lip GY. Relationship between plasma markers of endothelial cell integrity and the Framingham cardiovascular disease risk-factor scores in apparently healthy individuals. Blood Coagul Fibrinolysis 2002; 13(6): 513-518.
207. Felmeden DC, Spencer CG, Chung NA, Belgore FM, Blann AD, Beevers DG, et al. Relation of thrombogenesis in systemic hypertension to angiogenesis and endothelial damage/dysfunction (a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial[ASCOT]). Am J Cardiol 2003; 92(4): 400-405.
208. De Caterina R, Ghiadoni L, Taddei S, Virdis A, Almerigogna F, Basta G, et al. Soluble E-selectin in essential hypertension: a correlate of vascular structural changes. Am J Hypertens 2001; 14(3): 259-266.
209. Felmeden DC, Blann AD, Spencer CG, Beevers DG, Lip GY. A comparison of flow-mediated dilatation and von Willebrand factor as markers of endothelial cell function in health and in hypertension: relationship to cardiovascular risk and effects of treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial. Blood Coagul Fibrinolysis 2003; 14(5): 425-431.
210. Kaplan NM. The endothelium as prognostic factor and therapeutic target: what criteria should we apply? J Cardiovasc Pharmacol 1998; 32 Suppl 3: S78-S80.
211. Panza JA, Casino PR, Badar DM, Quyyumi AA. Effect of increased availability of endothelium-derived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension. Circulation 1993; 87(5): 1475-1481.
212. Luscher TF, Haefeli WE. L-arginine in the clinical arena: tool or remedy? Circulation 1993; 87(5): 1746-1748.
213. Machin S, Clarke C, Ikemura O, Kageyama S, Mackie IJ, Talbot IJ, et al. A humanized monoclonal antibody against vWF A1 domain inhibits vWF: RiCof activity and platelet adhesion in human volunteers. J Thromb Haemostat 2003; 1 (Suppl 1): 328 (Abstract).
214. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21(6): 1011-1053.
215. Panza JA, Quyyumi AA, Callahan TS, Epstein SE. Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. J Am Coll Cardiol 1993; 21(5): 1145-1151.
216. Creager MA, Roddy MA, Coleman SM. the effects of ACE inhibition on endothlium dependant vasodilatation. J Vasc Res 1992; 29: 97.
217. Treasure CB, Manoukian SV, Klein JL, Vita JA, Nabel EG, Renwick GH, et al. Epicardial coronary artery responses to acetylcholine are impaired in hypertensive patients. Circ Res 1992; 71(4): 776-781.
218. Treasure CB, Klein JL, Vita JA, Manoukian SV, Renwick GH, Selwyn AP, et al. Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels. Circulation 1993; 87(1): 86-93.
219. Kiefer FN, Neysari S, Humar R, Li W, Munk VC, Battegay EJ. Hypertension and angiogenesis. Curr Pharm Design 2003; 9(21): 1733-44.
220. MacFadyen RJ, Lip GY, Davis R. Hypertension to heart failure: new developmental strategies do not cross a clinical and therapeutic divide. Curr Pharm Design 2003; 9(21): 1665-78.
221. Taddei S, Ghiadoni L, Virdis A, Versari D, Salvetti A. Mechanisms of endothelial dysfunction: clinical significance and preventive non-pharmacological therapeutic strategies. Curr Pharm Design 2003; 9(29): 2385-402.